Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans
- PMID: 22582209
- PMCID: PMC3888111
- DOI: 10.1093/aje/kws196
Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans
Abstract
Because of widespread distribution of the influenza A (H1N1) 2009 monovalent vaccine (pH1N1 vaccine) and the prior association between Guillain-Barré syndrome (GBS) and the 1976 H1N1 influenza vaccine, enhanced surveillance was implemented to estimate the magnitude of any increased GBS risk following administration of pH1N1 vaccine. The authors conducted active, population-based surveillance for incident cases of GBS among 45 million persons residing at 10 Emerging Infections Program sites during October 2009-May 2010; GBS was defined according to published criteria. The authors determined medical and vaccine history for GBS cases through medical record review and patient interviews. The authors used vaccine coverage data to estimate person-time exposed and unexposed to pH1N1 vaccine and calculated age- and sex-adjusted rate ratios comparing GBS incidence in these groups, as well as age- and sex-adjusted numbers of excess GBS cases. The authors received 411 reports of confirmed or probable GBS. The rate of GBS immediately following pH1N1 vaccination was 57% higher than in person-time unexposed to vaccine (adjusted rate ratio = 1.57, 95% confidence interval: 1.02, 2.21), corresponding to 0.74 excess GBS cases per million pH1N1 vaccine doses (95% confidence interval: 0.04, 1.56). This excess risk was much smaller than that observed during the 1976 vaccine campaign and was comparable to some previous seasonal influenza vaccine risk assessments.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3888111/bin/amjepidkws196f01_ht.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3888111/bin/amjepidkws196f02_ht.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3888111/bin/amjepidkws196f03_ht.gif)
Comment in
-
Invited commentary: Influenza vaccine and Guillain-Barre syndrome--is there a risk?Am J Epidemiol. 2012 Jun 1;175(11):1129-32. doi: 10.1093/aje/kws194. Epub 2012 May 11. Am J Epidemiol. 2012. PMID: 22582208
Similar articles
-
Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence.Clin Infect Dis. 2014 Apr;58(8):1149-55. doi: 10.1093/cid/ciu005. Epub 2014 Jan 9. Clin Infect Dis. 2014. PMID: 24415636 Review.
-
Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe.PLoS One. 2014 Jan 3;9(1):e82222. doi: 10.1371/journal.pone.0082222. eCollection 2014. PLoS One. 2014. PMID: 24404128 Free PMC article.
-
Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.Am J Epidemiol. 2012 Jun 1;175(11):1100-9. doi: 10.1093/aje/kws195. Epub 2012 May 11. Am J Epidemiol. 2012. PMID: 22582210 Free PMC article.
-
Guillain-Barré syndrome after exposure to influenza virus.Lancet Infect Dis. 2010 Sep;10(9):643-51. doi: 10.1016/S1473-3099(10)70140-7. Lancet Infect Dis. 2010. PMID: 20797646 Review.
-
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.MMWR Morb Mortal Wkly Rep. 2010 Jun 4;59(21):657-61. MMWR Morb Mortal Wkly Rep. 2010. PMID: 20520590
Cited by
-
Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review.Glob Epidemiol. 2023 Jan 11;5:100098. doi: 10.1016/j.gloepi.2023.100098. eCollection 2023 Dec. Glob Epidemiol. 2023. PMID: 37638372 Free PMC article. Review.
-
Inflammatory demyelinating polyneuropathy after the ChAdOx1 nCoV-19 vaccine may follow a chronic course.J Neurol Sci. 2022 May 15;436:120231. doi: 10.1016/j.jns.2022.120231. Epub 2022 Mar 16. J Neurol Sci. 2022. PMID: 35313224 Free PMC article.
-
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022. Front Immunol. 2022. PMID: 35185881 Free PMC article.
-
Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.Front Immunol. 2021 Oct 6;12:744774. doi: 10.3389/fimmu.2021.744774. eCollection 2021. Front Immunol. 2021. PMID: 34691051 Free PMC article. Review.
-
Interpretation of vaccine associated neurological adverse events: a methodological and historical review.J Neurol. 2022 Jan;269(1):493-503. doi: 10.1007/s00415-021-10747-8. Epub 2021 Aug 16. J Neurol. 2022. PMID: 34398270 Free PMC article. Review.
References
-
- Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653–1666. - PubMed
-
- Haber P, Sejvar J, Mikaeloff Y, et al. Vaccines and Guillain-Barré syndrome. Drug Saf. 2009;32(4):309–323. - PubMed
-
- Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol. 1984;119(6):841–879. - PubMed
-
- Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110(2):105–123. - PubMed